EFFECT OF PSQI SCORE ON ADMINISTRATION MELATONIN IN PERIMENOPAUSE WOMEN
DOI:
https://doi.org/10.22159/ijcpr.2020v12i4.39097Keywords:
Perimenopause, Melatonin, PSQIAbstract
Objective: Determine the effect of melatonin administration on sleep quality perimenopausal women based on PSQI and compare the results of PSQI before and after treatment.
Methods: This study uses an experimental analytic study with Case Control design to determine the effect of melatonin administration on sleep quality perimenopausal women based on PSQI and compare the results of PSQI before and after treatment. This research was conducted at the Department of Obstetrics and Gynecology, H. Adam Malik General Hospital, Medan. The study population was all perimenopausal women who met the inclusion and exclusion criteria. This research was conducted from February to March 2020 with a sample of 25 people.
Results: PSQI scores in the control group by age were 4.0±1.0 in the age group>50 y from 8.0±1.0; 2.17±1.62 in the group with tertiary education from 5.83±1.69; 2.56±1.67 in the non-working group of 6.44±1.51 and 2.31±1.6 in the multipara group of 6.0±1.58. From the analysis results obtained a value of P<0.001. This also showed a significant difference in the PSQI score in the control group. significant differences in PSQI values in the control group and melatonin group in the case group before getting melatonin (p<0.001), whereas after administering melatonin, no difference in PSQI score was found in the groups that received melatonin and the control group (p = 0.657)
Conclusion: There are differences in PSQI scores in the case group before and after the administration of melatonin, in the control group who did not get melatonin and the difference in PSQI scores in the case group and the control group before treatment, but there were no differences in PSQI score in the case and control groups after treatment.
Downloads
References
2. Burger HG, Dudley E, Mamers P, Groome N, Robertson DM. Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol. Climacteric 2000;3:17-24.
3. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstetrics Gynecol Clin North America 2011;38:455-66.
4. Freeman EW, Sammel MD, Lin H. Temporal associations of hot flashes and depression in the transition to menopause. Menopause (New York, NY) 2009;16:728-34.
5. Freeman EW, Sammel MD, Gross SA, Pien GW. Poor sleep in relation to natural menopause: a population-based 14-year follow-up of midlife women. Menopause (New York, NY) 2015;22:719-26.
6. Dennerstein L, Lehert P, Guthrie JR, Burger HG. Modeling women's health during the menopausal transition: a longitudinal analysis. Menopause (New York, NY) 2007;14:53-62.
7. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S. Prevalence of sleep disorders in the los angeles metropolitan area. Am J Psychiatry 1979;136:1257-62.
8. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstetrics Gynecol Clin North America 2011;38:567-86.
9. Durant C, Christmas D, Nutt D. The pharmacology of anxiety. Curr Top Behav Neurosci 2010;2:303-30.
10. Polo Kantola P, Saaresranta T, Lampio LRF, Perez Lopez. editors. United States: Springers International Publishing; 2019.
11. Vural EM, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging 2014;31:441-51.
12. Smyth C. The pittsburgh sleep quality index (PSQI). Director 2000;8:28-9.
13. Ferracioli Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PloS One 2013;8:e63773
Published
How to Cite
Issue
Section
